
<ns0:uwmetadata xmlns:ns0="http://phaidra.univie.ac.at/XML/metadata/V1.0" xmlns:ns1="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0" xmlns:ns10="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0" xmlns:ns11="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0/entity" xmlns:ns12="http://phaidra.univie.ac.at/XML/metadata/digitalbook/V1.0" xmlns:ns13="http://phaidra.univie.ac.at/XML/metadata/etheses/V1.0" xmlns:ns2="http://phaidra.univie.ac.at/XML/metadata/extended/V1.0" xmlns:ns3="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/entity" xmlns:ns4="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/requirement" xmlns:ns5="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/educational" xmlns:ns6="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/annotation" xmlns:ns7="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/classification" xmlns:ns8="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/organization" xmlns:ns9="http://phaidra.univie.ac.at/XML/metadata/histkult/V1.0">
  <ns1:general>
    <ns1:identifier>o:17567</ns1:identifier>
    <ns1:title language="sr">Određivanje anizomicina tečnom hromatografijom sa tandem masenom spektrometrijom i elektrohemijskim metodama i primena na ispitivanje stabilnosti leka i njegove raspodele u tkivima pacova</ns1:title>
    <ns2:subtitle language="sr">doktorska disertacija</ns2:subtitle>
    <ns2:alt_title language="en">Determination of anisomycin by liquid chromatography with tandem mass spectrometry and electrochemical methods and application to investigation of drug stability and its distribution in rat tissues  : doctoral dissertation</ns2:alt_title>
    <ns1:language>sr</ns1:language>
    <ns1:description language="sr">Lek anizomicin je potencijalni imunosupresor pri niskim dozama (≤ 0,1 μM). TakoĎe ima potencijalnu primenu kao psihofarmaceutik i antikancerogeni lek, a u novijim istraţivanjima se pokazalo da je potencijalni radioprotektor. I pored višestruke potencijalne primene anizomicina, još uvek nema podataka o njegovoj kliničkoj primeni. Zbog toga je potrebno poznavanje farmakokinetičkih svojstava leka, pre svega poznavanje principa raspodele leka u organizmu i najznačajnijih farmakokinetičkih parametara. TakoĎe, da bi se utvrdio kvalitet leka i bezbednost njegovog korišćenja, potrebno je pratiti stabilnost i odrediti degradacione proizvode koji mogu nastati tokom proizvodnje, rukovanja ili čuvanja leka...</ns1:description>
    <ns1:description language="en">Drug anisomycin is a potential immunosuppressant in low doses (≤ 0.1 μM). It also has the potential use as a psychopharmaceutical and an anticancerous drug, and in the recent investigations it was shown that it is a potential radioprotector. Despite of multiple potential applications of anisomysin, its clinical use has not been reported yet. In that order, it is necessary to understand the pharmacokinetic properties of the drug, primarily its body distribution and the most important pharmacokinetic parameters. Also, in order to establish quality of the drug and safety of its use, it is required to monitor its stability and to determine its degradation products that may be formed during production, handling or storage...</ns1:description>
    <ns1:description language="sr">Hemijske nauke / Chemical sciences  Datum odbrane: 09.03.2018. </ns1:description>
    <ns1:keyword language="sr">anizomicin, tečna hromatografija–tandem masena spektrometrija, elektrohemijske metode, biološki materijal, raspodela leka u tkivima, farmakokinetički parametri, forsirana degradacija</ns1:keyword>
    <ns1:keyword language="en">anisomycin, liquid chromatography–tandem mass spectrometry, electrochemical methods, biological material, tissue distribution of the drug, pharmacokinetic parameters, forced degradation</ns1:keyword>
    <ns2:irdata>yes</ns2:irdata>
    <ns2:identifiers>
      <ns2:identifier>50003215</ns2:identifier>
    </ns2:identifiers>
    <ns2:identifiers>
      <ns2:resource>91552101</ns2:resource>
      <ns2:identifier>5745</ns2:identifier>
    </ns2:identifiers>
    <ns2:identifiers>     
 <ns2:resource>91552100</ns2:resource>
      <ns2:identifier>50003215</ns2:identifier>
    </ns2:identifiers>
  </ns1:general>
  <ns1:lifecycle>
    <ns1:upload_date>2018-04-23T14:19:24.053Z</ns1:upload_date>
    <ns1:status>45</ns1:status>
    <ns2:peer_reviewed>no</ns2:peer_reviewed>
    <ns1:contribute seq="0">
      <ns1:role>46</ns1:role>
      <ns1:ext_role>mentor</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Ljiljana M., 1986- </ns3:firstname>
        <ns3:lastname>Tolić</ns3:lastname>
      </ns1:entity>
      <ns1:date>2017</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="1">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>mentor</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Mila, 1951- </ns3:firstname>
        <ns3:lastname>Laušević</ns3:lastname>
      </ns1:entity>
      <ns1:date>2017</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="2">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Svetlana, 1973- </ns3:firstname>
        <ns3:lastname>Grujić</ns3:lastname>
      </ns1:entity>
      <ns1:date>2017</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="3">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Slobodan, 1950- </ns3:firstname>
        <ns3:lastname>Petrović</ns3:lastname>
      </ns1:entity>
      <ns1:date>2017</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="4">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Slavica, 1960- </ns3:firstname>
        <ns3:lastname>Ražić</ns3:lastname>
      </ns1:entity>
      <ns1:date>2017</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="5">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Branislava, 1963- </ns3:firstname>
        <ns3:lastname>Miljković</ns3:lastname>
      </ns1:entity>
      <ns1:date>2017</ns1:date>
    </ns1:contribute>
  </ns1:lifecycle>
  <ns1:technical>
    <ns1:format>122 lista</ns1:format>
    <ns1:size>5567672</ns1:size>
    <ns1:location>http://phaidrabg.bg.ac.rs/o:17567</ns1:location>
  </ns1:technical>
  <ns1:rights>
    <ns1:cost>no</ns1:cost>
    <ns1:copyright>yes</ns1:copyright>
    <ns1:license>4</ns1:license>
  </ns1:rights>
  <ns1:annotation>
    <ns6:annotations>
      <ns6:date>2018-04-23T14:19:24.320Z</ns6:date>
    </ns6:annotations>
  </ns1:annotation>
  <ns1:classification>
    <ns1:purpose>70</ns1:purpose>
    <ns7:taxonpath>
      <ns7:source>11</ns7:source>
      <ns7:taxon seq="0">1067197</ns7:taxon>
      <ns7:taxon seq="1">1067378</ns7:taxon>
      <ns7:taxon seq="2">1067387</ns7:taxon>
    </ns7:taxonpath>
    <ns7:taxonpath>
      <ns7:source>11</ns7:source>
      <ns7:taxon seq="0">1067094</ns7:taxon>
      <ns7:taxon seq="1">1067105</ns7:taxon>
    </ns7:taxonpath>
    <ns7:keyword language="sr" seq="0">anizomicin, tečna hromatografija–tandem masena spektrometrija, elektrohemijske metode, biološki materijal, raspodela leka u tkivima, farmakokinetički parametri, forsirana degradacija</ns7:keyword>
    <ns7:keyword language="en" seq="1">anisomycin, liquid chromatography–tandem mass spectrometry, electrochemical methods, biological material, tissue distribution of the drug, pharmacokinetic parameters, forced degradation</ns7:keyword>
  </ns1:classification>
  <ns1:organization>
    <ns8:hoschtyp>1738</ns8:hoschtyp>
    <ns8:orgassignment>
      <ns8:faculty>11A41</ns8:faculty>
    </ns8:orgassignment>
  </ns1:organization>
  <ns12:digitalbook>
    <ns12:releaseyear>2017</ns12:releaseyear>
  </ns12:digitalbook>
</ns0:uwmetadata>
